Cargando…
High-Throughput Profiling of Anti-Glycan Humoral Responses to SIV Vaccination and Challenge
Recent progress toward an HIV vaccine highlights both the potential of vaccines to end the AIDS pandemic and the need to boost efficacy by incorporating additional vaccine strategies. Although many aspects of the immune response can contribute to vaccine efficacy, the key factors have not been defin...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3781036/ https://www.ncbi.nlm.nih.gov/pubmed/24086502 http://dx.doi.org/10.1371/journal.pone.0075302 |
_version_ | 1782285353750626304 |
---|---|
author | Campbell, Christopher T. Llewellyn, Sean R. Damberg, Thorsten Morgan, Ian L. Robert-Guroff, Marjorie Gildersleeve, Jeffrey C. |
author_facet | Campbell, Christopher T. Llewellyn, Sean R. Damberg, Thorsten Morgan, Ian L. Robert-Guroff, Marjorie Gildersleeve, Jeffrey C. |
author_sort | Campbell, Christopher T. |
collection | PubMed |
description | Recent progress toward an HIV vaccine highlights both the potential of vaccines to end the AIDS pandemic and the need to boost efficacy by incorporating additional vaccine strategies. Although many aspects of the immune response can contribute to vaccine efficacy, the key factors have not been defined fully yet. A particular area that may yield new insights is anti-glycan immune responses, such as those against the glycan shield that HIV uses to evade the immune system. In this study, we used glycan microarray technology to evaluate anti-glycan antibody responses induced by SIV vaccination and infection in a non-human primate model of HIV infection. This comprehensive profiling of circulating anti-glycan antibodies found changes in anti-glycan antibody levels after both vaccination with the Ad5hr-SIV vaccine and SIV infection. Notably, SIV infection produced generalized declines in anti-glycan IgM antibodies in a number of animals. Additionally, some infected animals generated antibodies to the Tn antigen, which is a cryptic tumor-associated antigen exposed by premature termination of O-linked glycans; however, the Ad5hr-SIV vaccine did not induce anti-Tn IgG antibodies. Overall, this study demonstrates the potential contributions that glycan microarrays can make for HIV vaccine development. |
format | Online Article Text |
id | pubmed-3781036 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-37810362013-10-01 High-Throughput Profiling of Anti-Glycan Humoral Responses to SIV Vaccination and Challenge Campbell, Christopher T. Llewellyn, Sean R. Damberg, Thorsten Morgan, Ian L. Robert-Guroff, Marjorie Gildersleeve, Jeffrey C. PLoS One Research Article Recent progress toward an HIV vaccine highlights both the potential of vaccines to end the AIDS pandemic and the need to boost efficacy by incorporating additional vaccine strategies. Although many aspects of the immune response can contribute to vaccine efficacy, the key factors have not been defined fully yet. A particular area that may yield new insights is anti-glycan immune responses, such as those against the glycan shield that HIV uses to evade the immune system. In this study, we used glycan microarray technology to evaluate anti-glycan antibody responses induced by SIV vaccination and infection in a non-human primate model of HIV infection. This comprehensive profiling of circulating anti-glycan antibodies found changes in anti-glycan antibody levels after both vaccination with the Ad5hr-SIV vaccine and SIV infection. Notably, SIV infection produced generalized declines in anti-glycan IgM antibodies in a number of animals. Additionally, some infected animals generated antibodies to the Tn antigen, which is a cryptic tumor-associated antigen exposed by premature termination of O-linked glycans; however, the Ad5hr-SIV vaccine did not induce anti-Tn IgG antibodies. Overall, this study demonstrates the potential contributions that glycan microarrays can make for HIV vaccine development. Public Library of Science 2013-09-23 /pmc/articles/PMC3781036/ /pubmed/24086502 http://dx.doi.org/10.1371/journal.pone.0075302 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. |
spellingShingle | Research Article Campbell, Christopher T. Llewellyn, Sean R. Damberg, Thorsten Morgan, Ian L. Robert-Guroff, Marjorie Gildersleeve, Jeffrey C. High-Throughput Profiling of Anti-Glycan Humoral Responses to SIV Vaccination and Challenge |
title | High-Throughput Profiling of Anti-Glycan Humoral Responses to SIV Vaccination and Challenge |
title_full | High-Throughput Profiling of Anti-Glycan Humoral Responses to SIV Vaccination and Challenge |
title_fullStr | High-Throughput Profiling of Anti-Glycan Humoral Responses to SIV Vaccination and Challenge |
title_full_unstemmed | High-Throughput Profiling of Anti-Glycan Humoral Responses to SIV Vaccination and Challenge |
title_short | High-Throughput Profiling of Anti-Glycan Humoral Responses to SIV Vaccination and Challenge |
title_sort | high-throughput profiling of anti-glycan humoral responses to siv vaccination and challenge |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3781036/ https://www.ncbi.nlm.nih.gov/pubmed/24086502 http://dx.doi.org/10.1371/journal.pone.0075302 |
work_keys_str_mv | AT campbellchristophert highthroughputprofilingofantiglycanhumoralresponsestosivvaccinationandchallenge AT llewellynseanr highthroughputprofilingofantiglycanhumoralresponsestosivvaccinationandchallenge AT dambergthorsten highthroughputprofilingofantiglycanhumoralresponsestosivvaccinationandchallenge AT morganianl highthroughputprofilingofantiglycanhumoralresponsestosivvaccinationandchallenge AT robertguroffmarjorie highthroughputprofilingofantiglycanhumoralresponsestosivvaccinationandchallenge AT gildersleevejeffreyc highthroughputprofilingofantiglycanhumoralresponsestosivvaccinationandchallenge |